Company Overview of Xencor, Inc.
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company’s lead XmAb-engineered antibodies include XmAb5871, a B-cell inhibitor, which is in Phase Ib/IIa clinical trials for the treatment of autoimmune diseases; XmAb7195, an IgE inhibitor that is in Phase Ib clinical trials initiation to treat asthma and allergic diseases; and XmAb5574/MOR208, a Cytotoxic B-cell depleting product candidate, which is in Phase II clinical t...
111 West Lemon Avenue
Monrovia, CA 91016
Founded in 1997
Key Executives for Xencor, Inc.
Co-Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $400.0K
Chief Medical Officer
Total Annual Compensation: $369.0K
Chief Business Officer
Total Annual Compensation: $290.0K
Chief Scientific Officer and Senior Vice President of Research
Total Annual Compensation: $289.3K
Compensation as of Fiscal Year 2014.
Xencor, Inc. Key Developments
Xencor, Inc. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 01:55 PM
Sep 24 15
Xencor, Inc. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 01:55 PM. Venue: Le Parker Meridien Hotel, New York, New York, United States. Speakers: Bassil I. Dahiyat, Co-Founder, Chief Executive Officer, President and Director.
Xencor's Partner CSL Limited Initiates Phase 2 Clinical Trial of Biologic Candidate Using XmAb Cytotoxic Fc Domain
Sep 24 15
Xencor, Inc. announced that its partner CSL Limited has initiated, through its licensee Janssen Biotech Inc., a Phase 2 clinical trial for CSL362 (now called JNJ-56022473), which uses Xencor's XmAb Cytotoxic Fc Domain. Xencor will receive an undisclosed milestone payment for the initiation of Phase 2 testing. Under the terms of the agreement signed in February 2009, Xencor granted CSL Limited a non-exclusive license to Xencor Cytotoxic Fc Domains for use in CSL programs, including CSL362. Xencor is also eligible to receive additional milestone payments and royalties on sales. In 2013, CSL Limited licensed CSL362 to Janssen Biotech Inc.
Amgen, Xencor Enter into a Research and License Agreement to Develop Cancer Immunotherapy Treatments
Sep 23 15
Amgen and Xencor entered into a research and license agreement that could be worth as much as $1.7 billion to develop and commercialize therapeutics focused on cancer immunotherapy and inflammation. Under the partnership, Amgen will be in charge of preclinical and clinical development and commercialization, drawing on its background in protein therapeutics, while Xencor will contribute molecular engineering and bispecific molecules through its trademarked XmAb technology platform. The drug discovery will center on five Amgen-suggested antibody programs, and one specifically dedicated to multiple myeloma. Financially, Amgen will pay Xencor $45 million upfront and up to $1.7 billion for potential clinical, regulatory and sales milestones for six oncology programs, the companies said. Xencor could also receive royalties for developed medications and use of its CD38 bispecific T cell engager.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|